- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- EGFR positive
- EGFR negative
- PD-L1 negative
- PR positive
- BRAF positive
- ER negative
- ALK negative
- PR negative
- KRAS positive
- p16 positive
- ALK positive
- BRAF negative
- MET positive
- CD20 positive
- BRCA1 positive
- HR positive
- IDH positive
- BRCA2 positive
- HLA-A positive
- ROS1 negative
- PIK3CA positive
- ROS1 positive
- IDH negative
- TP53 positive
- HLA positive
- MYC positive
- BCR-ABL1 positive
- RET positive
- dMMR positive
- p16 negative
- BRCA positive
- MET negative
- MSI-H positive
- NTRK positive
- FLT3 positive
- HPV positive
- RAS positive
- anti-dsDNA positive
- ANA positive
- CD123 positive
- HPV negative
- NF1 positive
- PALB2 positive
- BCL2 positive
- FGFR2 positive
- HBsAg positive
- HLA negative
- NTRK negative
- RAS negative
- RET negative
- TP53 negative
- BCL6 positive
- CCND1 positive
- FGFR positive
- HLA-A negative
- KRAS negative
- MLH1 positive
- MSH2 positive
- MSH6 positive
- MSS positive
- NRAS positive
- PMS2 positive
- RB1 negative
- RB1 positive
- ctDNA positive
- ABCA4 positive
- CD19 positive
- CFTR positive
- CLDN18.2 positive
- KIT positive
- KMT2A positive
- L858R positive
- MGMT negative
- MMR positive
- NTRK1 positive
- PD-1 positive
- PTEN positive
- Philadelphia Chromosome positive
- RAF positive
- RF positive
- TROP2 negative
- TROP2 positive
- anti-Sm positive
- pMMR positive
- APC positive
- APP positive
- ATM positive
- BRCA1 negative
- BRCA2 negative
- C5 positive
- CD22 positive
- CD30 positive
- COL7A1 positive
- EBV positive
- Ex19del positive
- FMR1 positive
- HBV DNA positive
- HEXA positive
- HEXB positive
- HPV16 positive
- HbSS positive
- JAK2 positive
- Ki67 positive
- MDM2 positive
- MGMT positive
- MMR negative
- MSI positive
- MSI-H negative
- NF2 positive
- PD-1 negative
- PKLR positive
- PSEN1 positive
- PSEN2 positive
- RHO positive
- SMN1 positive
- SPINK5 positive
- TSC1 positive
- TSC2 positive
- anti-Ro autoantibodies positive
- dMMR negative
- t(11;14) positive
- \-17/abn(17p) positive
- \-5/del(5q) positive
- \-7 positive
- 11q negative
- 11q positive
- AKT negative
- ALPL positive
- Anti-Smith positive
- Aβ1-42 positive
- BRCA negative
- CD5 positive
- COL1A1 positive
- COL1A2 positive
- Complex karyotype positive
- DLL3 positive
- DMD positive
- DMPK positive
- ER/PR positive
- EZH2 positive
- FAP positive
- FGFR1 positive
- FGFR3 positive
- FLT3 negative
- FOXO1 fusion negative
- GATA2 positive
- GPC3 positive
- GRN positive
- H3K27M positive
- HBB positive
- HBV DNA negative
- HBsAg negative
- HR negative
- HRAS positive
- HRD positive
- IDS positive
- IGHV positive
- KMT2A-r positive
- LKB1 positive
- MECOM positive
- MECP2 positive
- MSI negative
- MSS negative
- NPM1 positive
- NRAS negative
- PDE6A positive
- PDE6B positive
- PDGFRA positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PMM2 positive
- PTCH1 positive
- PTEN negative
- Philadelphia chromosome negative
- PiZZ positive
- RAF negative
- SMARCA4 positive
- SSTR positive
- STK11 positive
- T315I positive
- T790M positive
- TMB positive
- TTR positive
- ZnT8 positive
- anti-AChR positive
- anti-MuSK positive
- anti-PLA2R positive
- anti-Ro/SSA positive
- del(17p) positive
- inv(3)(q21.3q26.2) positive
- other sickle cell syndrome variants positive
- p53 positive
- t(14;16) positive
- t(3;3)(q21.3;q26.2) positive
- t(4;14) positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- Adjuvant Radiation Therapy
- Adjuvant Therapy (except reconstruction)
- Allogeneic Hematopoietic Cell Transplantation
- Anti-Seizure Medications (up to 2 types)
- Any Treatment Intervention Resulting in Improvement in Fatigue and Physical Function
- Any Treatment for Pancreatic Cancer
- Archival Tissue Block or Newly-Obtained Core Needle or Incisional Biopsy
- At least one prior tumor-directed therapy
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
5522 trials
Trials Without a Placebo
1
2
3
…50